Comparison of MK-6240 and Flortaucipir Tau PET for the Biological Staging of Alzheimer Disease
Marina Scop Medeiros1, Pamela L. Ferreira1, Bruna Bellaver1, Emma Ruppert1, Hussein Zalzale2, Carolina Soares1, Guilherme Bauer-Negrini1, Guilherme Povala1, Livia Amaral1, Firoza Lussier1, Dana Tudorascu1, Joseph Masdeu3, David Soleimani-Meigooni4, Juan Fortea5, Val Lowe6, Hwamee Oh7, Belen Pascual8, Brian Gordon9, Pedro Rosa-Neto10, Lucas Porcello Schilling11, Suzanne Baker12, Tharick Pascoal1
1University of Pittsburgh, 2Psychiatry, University of Pittsburgh, 3Houston Methodist Neurological Institute, 4University of California, San Francisco, 5Hospital of Sant Pau, 6Mayo Clinic, 7Brown University, 8Houston Methodist Hospital, 9Washington University, 10McGill, 11Pontifícia Universidade Católica do Rio Grande do Sul, 12Lawrence Berkeley National Laboratory
Objective:
We aim to compare the biological staging of Alzheimer Disease using two different tau PET tracers.
Background:
The Alzheimer’s Association workgroup criteria (AA-2024) suggest four biological stages based on PET imaging. However, the application of this framework may vary depending on the tau PET tracer used. Also, the distribution of clinical stages by biological stage may differ.
Design/Methods:
We stratified 182 amyloid-positive participants from the HEAD study (Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease) that underwent both [18F]MK-6240 and Flortaucipir tau PET. Four clinical stages (normal, transitional, MCI, and dementia) were defined based on the AA-2024 criteria. Within clinical stage-2 (transitional) we assessed subgroups: subjective cognitive decline (SCD), subtle objective cognitive decline (SOCD), and mild behavioral impairment (MBI). Logistic and linear models corrected by age and sex tested association of groups with amyloid and tau pathology. The biological staging was performed using tracer-specific thresholds for regional SUVR and testing three regions of interest schemes: (i)proposed by AA-2024, (ii)Braak stages, (iii)or single anatomical regions. Cohen’s weighted-kappa (K) statistic measured clinical-biological and between-tracer agreements.
Results:
Clinical stages showed progressively increased prevalence of Aβ-positivity and higher entorhinal tau PET pathology from cognitively normal (CN) to SOCD, MCI, and dementia, in both tracers. MBI and SCD groups showed no increased Aβ or tau pathology compared to CN. For this reason, only SOCD was considered part of stage 2 for following analyses. All tested biological staging strategies showed moderate agreement (Cohen's-kappa 0.34-0.59) with clinical stages for both MK-6240 and Flortaucipir.
Conclusions:
Our results support that AA-2024 biological and clinical stages show similar clinical-biological concordance using either Flortaucipir or MK-6240, although this can vary based on biological staging method. Only SOCD among transitional stage subgroups showed higher amyloid and tau burden compared to clinical stage 1, while SCD and MBI showed similar pathologic burden to the cognitively normal group.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.